Evidence map›Paper›PMID 18096393›Full record

ArticleBioorganic & medicinal chemistry2008

Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase.

Sergio H Szajnman, Guadalupe E García Liñares, Zhu-Hong Li, Cuiying Jiang, Melina Galizzi, Esteban J Bontempi, Marcela Ferella, Silvia N J Moreno, Roberto Docampo, Juan B Rodriguez

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. A Systematic Review ofFrontiers in microbiology · 2017
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Sergio H SzajnmanDepartamento de Química Orgánica and UMYMFOR (CONICET-FCEyN), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellón 2, Ciudad Universitaria, C1428EHA Buenos Aires, Argentina.
Guadalupe E García Liñares
Zhu-Hong Li
Cuiying Jiang
Melina Galizzi
Esteban J Bontempi
Marcela Ferella
Silvia N J Moreno
Roberto Docampo
Juan B Rodriguez
University of Georgia · USConsejo Nacional de Investigaciones Científicas y Técnicas · ARFundación Ciencias Exactas y Naturales · AR

Funding

The contractile vacuole of Trypanosoma cruziR01AI068647 · NIAID · UNIVERSITY OF GEORGIA · PI DOCAMPO, ROBERTO · 2006 to 2010
$1.8M
The isoprenoid pathway from Toxoplasma gondiiR21AI068467 · NIAID · UNIVERSITY OF GEORGIA · PI MORENO, SILVIA N · 2006 to 2007
$400k
NIAID NIH HHS AI68467NIAID NIH HHS AI-68647NIAID NIH HHS R01 AI068647NIAID NIH HHS R21 AI068467
6 · The paper itself

Abstract

The effect of a series of 2-alkylaminoethyl-1,1-bisphosphonic acids against proliferation of the clinically more relevant form of Trypanosoma cruzi, the etiologic agent of American trypanosomiasis (Chagas' disease), and against tachyzoites of Toxoplasma gondii has been studied. Most of these drugs exhibited an extremely potent inhibitory action against the intracellular form of T. cruzi, exhibiting IC(50) values at the low micromolar level. This cellular activity was associated with a strong inhibition of the enzymatic activity of T. cruzi farnesyl diphosphate synthase (TcFPPS), which constitutes a valid target for Chagas' disease chemotherapy. Compound 17 was an effective agent against amastigotes exhibiting an IC(50) value of 0.84 microM, while this compound showed an IC(50) value of 0.49 microM against the target enzyme TcFPPS. Interestingly, compound 19 was very effective against both T. cruzi and T. gondii exhibiting IC(50) values of 4.1 microM and 2.6 microM, respectively. In this case, 19 inhibited at least two different enzymes of T. cruzi (TcFPPS and solanesyl diphosphate synthase (TcSPPS); 1.01 microM and 0.25 microM, respectively), while it inhibited TgFPPS in T. gondii. In general, this family of drugs was less effective against the activity of T. cruzi SPPS and against T. gondii growth in vitro. As bisphosphonate-containing compounds are FDA-approved drugs for the treatment of bone resorption disorders, their potential low toxicity makes them good candidates to control tropical diseases.

Indexed as

AnimalsAntiprotozoal AgentsDiphosphonatesEnzyme InhibitorsGeranyltranstransferaseInhibitory Concentration 50Structure-Activity RelationshipToxoplasmaTrypanosoma cruziAntiprotozoal AgentsDiphosphonatesEnzyme InhibitorsGeranyltranstransferase

Identifiers

PMID18096393
PMCPMC2330165
OpenAlexW2002294778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.